By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Camurus 

Ideon Science Park
Solvegatan 41
Lund    SE-22370  Sweden
Phone: 46-46-2865730 Fax: 46-46-2865739


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





Company News
Braeburn Pharma And Camurus Announce Positive Top-Line Phase 3 Results For Long-Acting Buprenorphine (CAM2038) For Treatment Of Opioid Addiction 11/14/2016 6:30:35 AM
Braeburn Pharma And Camurus Expand Collaboration And License Agreement To Include New Combination Product For Pain and Nausea 10/24/2016 12:32:34 PM
Braeburn Pharma And Camurus Expand Collaboration And License Agreement To Include New Combination Product For Pain And Nausea 10/24/2016 6:52:44 AM
Braeburn Pharma And Camurus Enroll First Patients In A Phase 3 Efficacy Trial Of CAM2038 For Treatment Of Chronic Low Back Pain 9/30/2016 6:45:22 AM
Camurus: Interim Report January-June 2016 7/14/2016 10:46:20 AM
Camurus Interim Report January-March 2016 5/17/2016 11:21:10 AM
Braeburn Pharma, Camurus Announce Positive Mid-Stage CAM2038 Data in Patients With Opioid Use Disorder 5/11/2016 6:02:32 AM
Camurus: Resolutions At The Annual General Meeting 2016 In Camurus 5/4/2016 11:12:22 AM
Camurus: Distribution Agreement Signed With R-PHARM US For Episil 4/21/2016 11:01:06 AM
Braeburn Pharma And Camurus Announce Enrollment Goals Reached In Two Pivotal Phase 3 Trials Of CAM2038 For Treatment Of Opioid Dependence 4/5/2016 8:29:16 AM
123
//-->